Summary
Despite Covid-related delays,
Management expects to top $10 million in annual revenue
There are several imminent developments that are potential catalysts for share price appreciation.
Else is conducting clinical trials to validate product benefits for targeted markets and for regulatory approval for infant formula, which is likely to become Else's lead product sometime next year.
She obviously doesn't understand what managing a publicly help startup should imply ...
COVID is irrelevant in our case
Focus and priorities are on research, 'development', 'clinical trials', ..
Projected sales of $10M hardly can justify the current MC of $125M, even assuming no increase in O/S. By the way, based on her forecast of a Q1 revenue (I took the $1,6 million) ... assuming a revenue growth of 10% Q to Q thereafter ... means that our FY 2022 total revenue would only be $7,5 millions. For getting a $9,9M revenue, a growht of revenues Q to Q would have to be 30%. I have a serious doubt that to be, unless major management decisions are made.
Unfortunately (I stand to be corrected) I believe her board and main advisors are (no doubt) reat scientific people but I also believe that Marketeers of experience are missing in her top executive team. Our CEO seams to believe that having good products is sufficient (Many found out how wrong such a belief can be) and that seems to be all she does focus on.
I for one, even if I believe in the products (actual and future) will reduce my position by 50% profiting from the next significant pps spike. I shall buyback in, whenever I feel someone has its main focus on 'market development' or when our market cap is based on a more justified multiplier.
So sorry ... GLTA
